###begin article-title 0
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 168 174 168 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2&#945;</sub>
###xml 119 127 <span type="species:ncbi:9606">patients</span>
In vitro allergen challenge of peripheral blood induces differential gene expression in mononuclear cells of asthmatic patients: inhibition of cytosolic phospholipase A2alpha overcomes the asthma-associated response
###end article-title 0
###begin p 1
Current address: AVEO Pharmaceuticals Inc., Cambridge, MA, USA.
###end p 1
###begin p 2
Current address: Genentech, South San Francisco, CA, USA.
###end p 2
###begin p 3
Current address: Clarus Ventures, Cambridge, MA, USA.
###end p 3
###begin p 4
Current address: TolerRx, Cambridge, MA, USA.
###end p 4
###begin title 5
Background
###end title 5
###begin p 6
###xml 326 327 326 327 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Existing treatments for asthma are not effective in all patients and disease exacerbations are common, highlighting the need for increased understanding of disease mechanisms and novel treatment strategies. The leukotriene pathway including the enzyme responsible for arachidonic acid release from cellular phospholipids, cPLA2alpha, is a major contributor to asthmatic responses and an attractive target in asthma therapies.
###end p 6
###begin title 7
Objective
###end title 7
###begin p 8
###xml 69 77 69 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 214 215 214 215 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The study reported here investigates (a) the differential effects of in vitro exposure of peripheral blood mononuclear cells (PBMCs) to allergen between asthma and healthy subjects, and (b) the contribution of cPLA2alpha to these differences in gene expression.
###end p 8
###begin title 9
Methods
###end title 9
###begin p 10
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
###xml 30 31 30 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 49 50 49 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In vitro responses of asthma (N=26) and healthy (N=11) subject PBMC samples to allergen stimulation in the presence and absence of cPLA2alpha inhibition or 5-lipoxygenase inhibition were compared at the gene expression level using oligonucleotide arrays and at the protein level using ELISA.
###end p 10
###begin title 11
Results
###end title 11
###begin p 12
Subject samples within both asthma and healthy groups showed allergen-dependent cytokine production and allergen-dependent gene expression changes, although transcriptional profiling identified 153 genes that were modulated significantly differently by allergen between asthma and healthy subjects. Among these were genes previously associated with asthma, but the majority (about 80%) have not previously been associated with asthma.
###end p 12
###begin title 13
Conclusions
###end title 13
###begin p 14
###xml 244 245 244 245 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Transcriptional profiling elucidated novel gene expression differences between the asthmatic and healthy subject samples. Although 5-lipoxygenase inhibition did not significantly affect allergen-modulated gene expression, the inhibition of cPLA2alpha activity affected many of the allergen-dependent, asthma-associated gene expression changes.
###end p 14
###begin p 15
###xml 0 13 0 13 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Cite this as:</italic>
###xml 241 274 241 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Clinical and Experimental Allergy</italic>
Cite this as: K. A. Whalen, H. Legault, C. Hang, A. Hill, M. Kasaian, D. Donaldson, G. W. Bensch, G. Bensch, J. Baker, P. S. Reddy, N. Wood, M. K. Ramarao, D. K. Ellis, C. Csimma, C. McKee, J. D. Clark, J. Ryan, A. J. Dorner and M. O'Toole, Clinical and Experimental Allergy, 2008 (38) 1590-1605.
###end p 15
###begin title 16
Introduction
###end title 16
###begin p 17
###xml 275 276 275 276 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b1">1</xref>
###xml 365 366 365 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b2">2</xref>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 474 482 <span type="species:ncbi:9606">patients</span>
###xml 520 528 <span type="species:ncbi:9606">patients</span>
Asthma is a complex airway disease characterized by reversible airway obstruction, bronchial hyperresponsiveness and airway inflammation. The prevalence of asthma has almost doubled in the past 20 years, with approximately 8-10% of the US population effected by the disease [1]. World-wide, over four billion dollars is spent on treating asthma patients each year [2]. Current asthma treatments target known disease mechanisms, but these treatments are not effective in all patients and suboptimal disease control among patients taking these medications is common. Additional insight into the pathogenesis and aetiology of asthma will facilitate development of more widely effective therapies.
###end p 17
###begin p 18
###xml 717 718 715 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b3">3</xref>
###xml 833 834 831 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b4">4</xref>
###xml 836 837 834 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b5">5</xref>
###xml 849 850 847 848 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b6">6</xref>
###xml 852 853 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b7">7</xref>
###xml 894 895 892 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b8">8</xref>
###xml 1083 1084 1076 1077 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1094 1095 1087 1088 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b9">9</xref>
###xml 1097 1099 1090 1092 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b10">10</xref>
Although the aetiology of asthma is multi-factorial, a common mechanism underlying the pathophysiology of asthma involves a dysregulated inflammatory response in the lung to environmental allergens. This ultimately results in increased vascular permeability, smooth muscle contraction, bronchoconstriction and inflammation. Asthma treatments currently available are designed to inhibit these physiologic processes. Corticosteriods and anti-allergy medicines, such as soluble IgE antibody (Xolair(R)) focus on inhibiting the dysregulated inflammatory response. A major characteristic of the inflammatory response is a shift in the balance of the immune response from a T-helper type 1 (Th1) to a Th2 cytokine profile [3]. Th2 cells mediate the inflammatory response through the release of cytokines including ILs, particularly IL-13 [4, 5] and IL-4 [6, 7] leading to IgE production and release [8] and therapies targeting these mediators are being developed. Other treatments counter bronchial airway narrowing, such as the bronchodilator salbutamol (Ventolin(R)), a short-acting beta2-agonist [9, 10].
###end p 18
###begin p 19
###xml 194 196 194 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b11">11</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b12">12</xref>
###xml 249 251 249 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b14">14</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b15">15</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b17">17</xref>
###xml 372 380 372 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 385 392 385 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 638 646 638 646 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 779 781 779 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b18">18</xref>
###xml 799 801 799 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b19">19</xref>
###xml 811 813 811 813 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b20">20</xref>
###xml 823 825 823 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b21">21</xref>
###xml 842 844 838 840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b22">22</xref>
###xml 846 848 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b23">23</xref>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
Reflecting the complexity of the disease, the therapies described above, and others currently available, do not consistently abrogate airway inflammation and airway remodelling in all patients [11]. Inter-individual variability in drug response [12-14] and frequent adverse drug reactions [15-17] to currently available drugs necessitate novel treatment strategies. Prior in vitro and in vivo studies have elucidated some critical mechanisms of asthma pathogenesis including the identification of some important mediators of allergen responsiveness. Previous studies on the differences between asthma and healthy subjects with respect to in vitro peripheral blood mononuclear cell (PBMC) response to allergen have focused on relatively well-characterized mediators such as IL-9 [18], IL-5 and IL-4 [19], IL-13 [20], IL-10 [21] and IFN-gamma [22, 23]. Although these findings are informative, they provide information for only a limited set of inflammatory targets based on known disease pathways.
###end p 19
###begin p 20
###xml 148 156 148 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 512 520 512 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 638 639 638 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 652 660 648 656 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 719 720 715 716 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 968 969 960 961 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 988 990 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 992 994 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 997 1004 989 996 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vivo</italic>
###xml 1023 1024 1015 1016 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1137 1139 1125 1127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b26">26</xref>
###xml 1153 1154 1141 1142 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1266 1268 1250 1252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 1301 1309 1285 1293 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1348 1349 1332 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1371 1373 1351 1353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b28">28</xref>
###xml 1427 1428 1407 1408 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1566 1568 1546 1548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1575 1576 1555 1556 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1666 1668 1646 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
###xml 1713 1714 1693 1694 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1755 1757 1735 1737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b29">29</xref>
###xml 1759 1761 1739 1741 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b31">31</xref>
###xml 1762 1764 1742 1744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b33">33</xref>
###xml 1884 1885 1864 1865 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1926 1934 1902 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1114 1119 <span type="species:ncbi:10090">mouse</span>
###xml 1243 1248 <span type="species:ncbi:9940">sheep</span>
###xml 1365 1369 <span type="species:ncbi:10090">mice</span>
A global transcriptional profiling study was designed to identify differentially responsive genes in PBMCs of asthma and healthy subjects following in vitro allergen challenge. This approach was aimed at facilitating the discovery of novel biomarkers and therapeutic candidates by revealing associations independent of an experimental system guided by prior knowledge. Cytokine production as assessed at the protein level by ELISAs was done in parallel to allow comparisons with established methods of assessing in vitro responsiveness. Additionally, transcriptional profiling was carried out to determine the effect of inhibition of cPLA2alpha on the in vitro allergen response of asthma and healthy subjects. The cPLA2alpha enzyme is an attractive target for inhibition in treatment of inflammatory diseases; the enzyme selectively releases arachidonic acid from cell membrane phospholipids to initiate the production of lipid mediators of inflammation including PGD2 and leukotrienes [24, 25]. In vivo inhibitors of cPLA2alpha have been shown to prevent the development of airway hyperresponsiveness (AHR) in a mouse model of asthma [26] and the cPLA2alpha inhibitor tested in the study reported here (WAY-196025) has shown efficacy in the sheep model of asthma [27]. In addition, antigen-specific in vitro T cell responses are deficient in cPLA2alpha knock-out mice [28]. Evidence indicates that downstream products of cPLA2 activity enhance inflammatory responses. LTs enhance phagocytic capacity and the generation of pro-inflammatory mediators by leucocytes [29]. cPLA2 also generates the lysophospholipid precursor of PAF - a lipid mediator of inflammation [30]. The potent chemoattractant activity of LTB4 for myeloid cells and T effector cells [29, 31-33] also points to an important role in pro-inflammatory cascades. Together, these findings prompted the testing of a cPLA2alpha inhibitor on the allergen-specific in vitro response associated with asthma.
###end p 20
###begin title 21
Methods
###end title 21
###begin title 22
Analytical samples
###end title 22
###begin p 23
###xml 548 549 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 589 590 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 624 625 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 633 634 631 632 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 667 668 663 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 677 678 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 770 772 764 766 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b34">34</xref>
###xml 1407 1414 1401 1408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl1">Table 1</xref>
###xml 485 493 <span type="species:ncbi:9606">children</span>
###xml 1141 1149 <span type="species:ncbi:9606">patients</span>
Twenty atopic and six non-atopic adult subjects with persistent asthma were recruited from the Allergy, Asthma and Dermatology Research Center in Lake Oswego, Oregon, and Bensch Research Associates in Stockton, California. Atopic status was confirmed by skin test in 15 of 20 subjects, and by clinical assessment in the remaining five subjects. Duration of disease ranged from 62 years to 1 year, with an average duration of 23 years. Ten of the subjects were diagnosed with asthma as children. Asthma subjects were categorized as mild persistent [N=4, forced expiratory volume in 1 s (FEV1) 92+/-20%], moderate persistent (N=11, FEV1 75+/-16%) or severe persistent (N=11, FFEV1 65+/-17%) according to the 1997 NIH Guidelines for the Diagnosis and Management of Asthma [34]. Each clinical site's Institutional Review Board or Ethics Committee approved this study, and the only study-specific procedure was sample collection. All asthma subjects were on standard of care treatment: 14 subjects were taking inhaled steroids, three were taking nasal steroids and nine both inhaled and nasal steroids. Samples collected included four (15%) from patients on oral steroids. Eleven healthy volunteers were recruited from Wyeth Research in Cambridge, MA, and had no known history of asthma or seasonal allergies. Informed consent was obtained from all subjects. Demographic information for the subjects is shown in Table 1. Blood was drawn into (8 mL x 6 tubes) cell purification tubes (Becton Dickinson, Franklin Lakes, NJ, USA). All asthma samples where shipped at room temperature in a temperature-controlled box overnight from the clinical site in the western US and processed immediately upon receipt in Andover, MA (approximately 24 h after blood draw). Healthy subject samples, which did not require shipping, were stored overnight before processing to mimic the conditions of the asthma samples. Therefore, both groups of samples were treated similarly to ensure that any observed differences between the groups were not attributable to differences in sample processing. PBMCs were isolated from whole blood samples according to the manufacturer's recommendations.
###end p 23
###begin p 24
Characteristics of study subjects
###end p 24
###begin p 25
M, male; F, female; y, years; NA, not applicable. Of the 20 atopics, allergy assessments were done by skin test for 13, the remaining were characterized as atopic through clinical assessment.
###end p 25
###begin title 26
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro cell stimulation
###end title 26
###begin p 27
###xml 26 34 26 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 42 43 42 43 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 871 879 871 879 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 881 883 881 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b35">35</xref>
###xml 1702 1704 1698 1700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b36">36</xref>
###xml 175 178 <span type="species:ncbi:9685">cat</span>
###xml 1013 1016 <span type="species:ncbi:9685">cat</span>
###xml 1195 1200 <span type="species:ncbi:9606">human</span>
The PBMCs were stimulated in vitro (2 x 105 cells/well, 96 well Costar-Corning CLS 3799) with a cocktail containing four different allergens from house dust mite, ragweed and cat. Recombinant allergens, Der p1, Der f2, Fel d1 (Indoor Biotech, Charlottesville, VA, USA) and natural ragweed allergen (Allergy Lab, Seattle, WA, USA) were screened for endotoxin levels (LAL Endotoxin Test, Catalog # HIT302, sensitivity, 0.0001 EU/mL; Cell Sciences, Canton, MA, USA), and allergen preparations were selected based on having the lowest endotoxin levels among available sources of these allergens. This was done to ensure endotoxin levels as low as could be achieved using purified natural allergens. The total level of endotoxin in allergen-stimulated cultures was 0.057 EU/mL, approximately 5.7 pg/mL, about 100-fold below the reported minimum required for endotoxin effects in vitro [35]. The final allergen cocktail concentrations in culture medium were as follows: Der p1 and Der f2 (dust mite), 1 mug/mL; Fel d1 (cat), 1.25 mug/mL; ragweed, 125 mug/mL. Antigen concentrations were chosen based on titration experiments (twofold dilutions starting at 10 mug/mL) performed using samples from four human donors before the initiation of work on the samples reported here. Optimal concentrations were chosen based on maximum cytokine production and antigen-dependent proliferation (data not shown). A time course was also performed (from 3 to 7 days) and 6 days was chosen as optimal (data not shown). The sensitivity of the subjects to the allergens used was unknown, but allergens were chosen based on the estimate that 80% of allergic individuals are believed to react to one or more of these allergens [36]. Culture medium contained RPMI-1640 (Sigma, St. Louis, MO, USA) with 10% heat-inactivated FCS (Sigma) and 100 unit/mL penicillin and 100 mug/mL streptomycin and 0.292 mug/mL glutamine (GIBCO RL Invitrogen, Carlsbad, CA, USA).
###end p 27
###begin p 28
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 75 76 70 71 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 148 149 142 143 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 366 368 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b37">37</xref>
###xml 463 465 457 459 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 470 471 464 465 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 543 545 537 539 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 569 570 550 551 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 637 639 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 720 721 701 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 726 727 707 708 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 732 733 713 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 741 742 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 799 800 775 776 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 872 873 848 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1018 1019 990 991 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1085 1086 1050 1051 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1100 1101 1061 1062 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1115 1116 1073 1074 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1130 1131 1084 1085 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1167 1169 1118 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b38">38</xref>
###xml 1186 1188 1137 1139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b39">39</xref>
###xml 1226 1227 1177 1178 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1330 1331 1278 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1471 1472 1416 1417 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1486 1487 1427 1428 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1524 1525 1462 1463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1539 1540 1473 1474 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1595 1596 1526 1527 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1661 1662 1589 1590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1756 1758 1681 1683 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 1772 1774 1697 1699 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">sn</italic>
###xml 1851 1852 1776 1777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1858 1860 1780 1782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b40">40</xref>
###xml 1960 1961 1875 1876 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2091 2092 2003 2004 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2275 2276 2172 2173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2289 2290 2182 2183 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2321 2322 2211 2212 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2338 2340 2224 2226 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">50</sub>
###xml 2344 2345 2230 2231 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2382 2383 2268 2269 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2402 2403 2288 2289 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2438 2439 2320 2321 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2505 2506 2386 2387 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2564 2565 2444 2445 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2579 2580 2458 2459 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sc>
###xml 2742 2743 2621 2622 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 274 279 <span type="species:ncbi:9606">human</span>
###xml 821 826 <span type="species:ncbi:9606">human</span>
The cPLA2alpha inhibitor, WAY-196025, was used at a concentration of 0.3 mum, and zileuton, the 5-lipoxygenase inhibitor, at a concentration of 5 mum in the PBMC samples. The inhibitory activity of the batches of WAY-196025 and zileuton used in this study was verified in a human whole blood assay stimulated with calcium ionophore, A23187, as described previously [37]. WAY-196025, was confirmed to inhibit both the prostaglandin and leukotriene pathways with IC50<15 nm and zileuton was shown to inhibit the 5-lipoxygenase pathway with an IC50 of approximately0.55 mum. The characterization of WAY-196025 has been described elsewhere [27]. In brief, WAY-196025 inhibits the production of arachidonate metabolites - TXB2, LTB4, PGE2 and PGF2alpha by 72%, 78%, 79% and 72%, respectively, at 0.039 mumin A23187 stimulated human whole blood. WAY-196025 is selective for cPLA2alpha in cell-based assays, does not inhibit COX-1 and COX-2 in microsomes, and is >1000-fold selective against the closely related enzymes, cPLA2beta and gamma. The identity within the lipase domain between cPLA2alpha and cPLA2beta, and cPLA2alpha and cPLA2zeta are 37% and 32%, respectively [38]. Ghosh et al. [39] have reported the inhibition of cPLA2zeta using an analogue of WAY-196025 they called 'Wyeth-1', but the selectivity for WAY-196025 for cPLA2zeta was not tested in the work reported by Ghosh et al. Within 10 A of the active site Ser-228, 25 of 51 residues are distinct between cPLA2alpha and cPLA2zeta and 29 of 51 differ between cPLA2alpha and cPLA2beta. To ascertain directly if WAY-196025 inhibits cPLA2zeta (PLA2G4F), Cos-M6 cells were transfected with pCMV6-XL6-cPLA2zeta (Origene ACC#NM_213600), cleared lysates were harvested and assayed using 1-palmitoyl-2-[14C]arachidonyl-sn-glycerophosphatidylcholine (PAPC) liposomes as described previously for cPLA2beta [40]. In a 10 min incubation at 37 degreesC, 1 mug of cleared lysate protein from cells expressing cPLA2zeta released 16.5 times as much free arachidonate as lysate from mock-transfected cells showing that the activity was due to cPLA2zeta. The amount of lysate had been titrated to give approximately10% conversion of substrate. Using these conditions in parallel assays performed in triplicate containing either cPLA2alpha or cPLA2zeta, WAY-196025 inhibited cPLA2alpha with an IC50=8 nm with 90% inhibition observed at 30 nm. In contrast, cPLA2zeta was inhibited only 30% at 2 mum. Higher concentrations of WAY-196025 were not tested because 2 mum is already 22% the concentration of the total lipid (6 mum PAPC and 3 mum dioleoyl glycerol) and therefore may be acting to disrupt the surface of the liposome (data not shown). Thus, WAY-196025 is minimally 250-fold selective for cPLA2alpha.
###end p 28
###begin p 29
After 6 days in culture, approximately 200 muL of supernatant was removed without disturbing the cell pellet using an eight-channel pipettor and placed into a collection plate for cytokine ELISA. To the remaining cell pellet, 100 muL of RLT lysis buffer containing 1% beta-mercaptoethanol was added and snap-frozen pending RNA purification (Qiagen, Valencia, CA, USA).
###end p 29
###begin title 30
Cytokine assays
###end title 30
###begin p 31
###xml 852 853 840 841 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 872 873 860 861 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
Levels of IFN-gamma, IL-5 and IL-13 in supernatants were measured by ELISA. Supernatant was added to pre-coated IFN-gamma, IL-5 and IL-13 ELISA plates (Pierce Endogen, Meridain, Rockford, IL, USA) according to the manufacturer's instructions. The appropriate biotinylated antibody for each cytokine was used and streptavidin-HRP was added and developed using 3,3', 5,5'-tetramethylbenzidine (TMB) substrate solution. Absorbance was measured by subtracting the 550 nm values from 450 nm values. Results were calculated using Softmax 4.7 software. The sensitivity of the assays was also within the limits of the manufacturer guidelines. The limit of detection was 2 pg/mL for IL-5, 7 pg/mL for IL-13 and 2 pg/mL for gamma-IFN. Allergen-specific levels were determined by comparing levels in the presence and absence of allergen. For a subset of samples (N=17 for asthma and N=9 for healthy subjects) for which sufficient RNA was available following GeneChip analysis, levels of cytokine RNA expression were measured using a custom Taqman low density array (TLDA) described as follows.
###end p 31
###begin title 32
RNA purification and microarray hybridization
###end title 32
###begin p 33
###xml 820 822 820 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b41">41</xref>
###xml 1114 1116 1114 1116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
Total RNA was isolated using the Rneasy mini kit (Qiagen). A phenol/chloroform extraction was performed, and the RNA was repurified using the Rneasy mini kit reagents. Eluted RNA was quantified using a Spectramax96 well plate UV reader (Molecular Devices, Sunnyvale, CA, USA) monitoring A260/280 OD values. The quality of each RNA sample was assessed by the integrity of the 28S and 18S peaks by capillary electrophoresis alongside an RNA molecular weight ladder on the Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). All procedures for assaying samples on GeneChips were performed by Expression Analysis (Expression Analysis, Inc. 2605 Meridian Parkway, Durham, NC, USA). Labelled targets for oligonucleotide arrays were prepared using a modification of the procedure described by Lockhart et al. [41]. Labelled targets were hybridized to the HG-U133A Affymetrix GeneChip Array as described in the Affymetrix technical manual. Eleven biotinylated control transcripts ranging in abundance from 3 parts per million (ppm) to 100 ppm were spiked into each sample to function as a standard curve [42]. GeneChip MAS 5.0 software was used to evaluate the hybridization intensity, compute the signal value for each probe set and make an absent/present call.
###end p 33
###begin title 34
Taqman low density arrays
###end title 34
###begin p 35
###xml 351 359 351 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Table S1</xref>
Both to confirm findings from GeneChip and to measure levels of cytokine RNA that were below GeneChip levels of detection, custom TLDA were designed using primers and probes as listed through the Applied Biosystems (Applied Biosystems, Foster City, CA, USA) website (). A 48-assay design was used and the individual assays are listed in supplementary Table S1. Briefly, for samples with sufficient RNA remaining following GeneChip measurements, 100 ng of total RNA was run for each sample per array and each sample was run in duplicate. The samples assayed by TLDA were the allergen-stimulated, allergen plus WAY-196025, and unstimulated sample sets from nine of the healthy and 17 asthma subjects. cDNA synthesis was carried out using a high capacity cDNA archive kit (Applied Biosystems, Product Number 4322171) according to the manufacturer's protocols. Each cDNA sample (50 muL) was added to an equal volume of 2 x TaqMan Universal PCR Master Mix (Applied Biosystems) and the resulting mixture was added to one of the eight channels on the array. The samples were loaded by centrifugation into the wells that contain the lyophilized primer probe sets. The card was then sealed and PCR amplification was performed using an Applied Biosystems Prism 7900HT sequence detection system according to the manufacturers protocols. (Thermal cycler conditions were as follows: 2 min at 50 degreesC, 10 min at 94.5 degreesC, 30 s at 97 degreesC, 1 min at 59.7 degreesC for 40 cycles. All steps were carried out according to the manufacturer's protocol).
###end p 35
###begin title 36
Taqman low density array analysis
###end title 36
###begin p 37
###xml 56 57 56 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 163 163 163 163 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu1.jpg" mimetype="image"/>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 258 259 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 359 360 359 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 360 361 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 542 542 542 542 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu2.jpg" mimetype="image"/>
###xml 718 718 718 718 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu3.jpg" mimetype="image"/>
###xml 736 736 736 736 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu4.jpg" mimetype="image"/>
Expression values were calculated using the comparative CT method as described (User Bulletin No. 2, Applied Biosystems). Briefly, this technique uses the formula  to calculate the expression of target genes normalized to a calibrator. The threshold cycle (CT) indicates the cycle number at which the amount of amplified target reaches a fixed threshold. The CT values range from 0 to 40 (the latter representing the default upper limit PCR cycle number that defines failure to detect a signal). The duplicate samples were averaged, then the  value was determined for each gene for each donor using the total gene set average as the calibrator. The fold change was determined for each donor by the following formula: ( allergen treated- no treatment control)=log fold change. The average log fold change was then determined for the healthy volunteer group and for the asthma group by averaging the individual fold changes.
###end p 37
###begin title 38
Data normalization and filtering of Affymetrix data
###end title 38
###begin p 39
###xml 301 302 298 299 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 351 353 348 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b42">42</xref>
GeneChips were required to pass the pre-set quality control criteria that the RNA quality metric required an average ratio of beta-actin and GAPDH 5'-3' probes sets >0.4. The signal value for each probe set was converted into a frequency value representative of the number of transcripts present in 106 transcripts by reference to the standard curve [42]. Data for 10 280 probe sets that were called 'present' in at least five of the samples and with a frequency of 10 ppm or more in at least one of the samples were subject to the statistical analysis described as follows, while probe sets that did not meet these criteria were excluded.
###end p 39
###begin title 40
Statistical analysis of Affymetrix data
###end title 40
###begin p 41
###xml 155 160 155 160 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anova</sc>
###xml 366 367 366 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 498 500 498 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b43">43</xref>
###xml 593 598 593 598 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">anova</sc>
The antigen-dependent fold change differences were calculated by determining the difference in the log-2 frequency in the presence and absence of antigen. anova was performed using this metric to identify allergen-dependent differences, and also to identify significant differences between the asthma and healthy groups with respect to the response to allergen. Raw P-values were adjusted for multiplicity of testing according to the false discovery rate (FDR) procedure of Benjamini and Hochberg [43] using Spotfire (Somerville, MA, USA). Significant effects of WAY-196025 were identified by anova comparing the log-2 differences in the groups treated with allergen to the groups treated with allergen and WAY-196025.
###end p 41
###begin title 42
Hierarchical clustering
###end title 42
###begin p 43
###xml 138 139 138 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">z</italic>
For hierarchical agglomerative clustering of probe sets and arrays, the log-2 scale MAS5 expression values from each probe set were first z-normalized so that each probe set had a mean expression level of zero and a standard deviation of 1 across all samples. Then, these normalized profiles were clustered hierarchically using UPGMA (unweighted average link) and the Euclidean distance measure.
###end p 43
###begin title 44
Ingenuity pathways analysis
###end title 44
###begin p 45
###xml 190 191 188 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 344 355 342 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Focus Genes</italic>
###xml 499 510 497 508 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Focus Genes</italic>
Data were analysed through the use of Ingenuity Pathways Analysis (IPA) (Ingenuity(R) Systems, Mountain View, CA, USA (). Asthma-associated gene identifiers and corresponding expression and P-values were uploaded into the application. Gene identifiers were mapped to the corresponding gene objects in the Ingenuity Pathways Knowledge Base. The Focus Genes were overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks of these Focus Genes were then algorithmically generated based on their connectivity. Functional analysis, canonical pathways and annotations for these genes were also obtained using IPA.
###end p 45
###begin title 46
Results
###end title 46
###begin title 47
###xml 0 8 0 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">In vitro</italic>
In vitro cytokine expression
###end title 47
###begin p 48
###xml 156 164 156 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b44">44</xref>
###xml 258 260 258 260 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b45">45</xref>
###xml 521 528 517 524 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl2">Table 2</xref>
We determined the allergen responsiveness of PBMC by measuring the levels of cytokines produced by the PBMC of asthma and healthy subjects following 6 days in vitro stimulation. A 6 day time-point was chosen because at both the mRNA [44] and protein levels [45], an effective response to allergen has been previously demonstrated and our pilot assays with protein and Taqman read-outs before the initiation of this study confirmed these results. ELISA analyses were carried out for IFN-gamma, IL-5 and IL-13. As shown in Table 2, all healthy volunteers and approximately 80% of asthma subjects showed a cytokine response to allergen defined as a 1.5-fold or greater increase in the production of at least one cytokine compared with baseline levels. Although the highest levels observed for Th2 cytokines IL-5 and IL-13 were in the asthma group and the highest levels of Th1 cytokine IFN-gamma were observed in the healthy group, the statistical power of this experiment was not sufficient to detect a significant difference between these groups with respect to allergen-specific cytokine production.
###end p 48
###begin p 49
Cytokine production in healthy and asthma subjects
###end p 49
###begin p 50
Production of cytokine was measured using ELISA assays on the supernatants from PBMCcultures after 6 day allergen stimulation as described in 'Methods'. Subjects were classified as positive responders if, in the presence of allergen, cytokine production was increased at least 1.5-fold. PBMC, peripheral blood mononuclear cell.
###end p 50
###begin p 51
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 199 200 195 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 246 247 242 243 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
The samples were also treated with the cPLA2alpha inhibitor WAY-196025 or zileuton in the presence of allergen and cytokine measurements were taken. Both drugs significantly reduced IL-13 secretion (P-value=0.001 for the WAY-196025 treatment and P-value=0.0005 for zileuton treatment) in the asthmatic samples. There was no significant effect on IL-5 or IFN-gamma levels (data not shown).
###end p 51
###begin p 52
###xml 389 397 385 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Table S1</xref>
###xml 631 632 627 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The 6-day cytokine RNA levels were also assessed using the custom TLDA. Twelve cytokines and two cytokine receptors were assayed: IFN-gamma, IL-10, IL-12B, IL-13, IL-15, IL-17A, IL-18, IL-21, IL-32, IL-4, IL-5, IL-9, IL-13RA1 and IL-21R. (Many of these genes were below the level of detection of the Affymetrix GeneChip). The full list of genes assayed by TLDA are listed in supplementary Table S1. By RNA expression level as measured by TLDA, IL-15 (FDR=0.01), IL-18 (FDR=0.02), IL-13-RA (FDR=0.049) had allergen-dependent changes that differed significantly (FDR<0.051) between asthma and healthy subjects. The inhibition of cPLA2alpha had a significant effect on expression of both IL-15 (FDR=0.0007) and IL-18 (FDR=0.009) in this assay.
###end p 52
###begin title 53
###xml 135 143 135 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Peripheral blood mononuclear cell expression profile demonstrates response to allergen in both the healthy and asthma groups following in vitro stimulation with allergen
###end title 53
###begin p 54
###xml 40 41 40 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 68 69 68 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 677 685 673 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD2">Table S2</xref>
###xml 720 722 716 718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b46">46</xref>
###xml 723 725 719 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 735 737 731 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b50">50</xref>
###xml 739 741 735 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b51">51</xref>
###xml 751 753 747 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b52">52</xref>
###xml 754 756 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b55">55</xref>
###xml 769 771 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b56">56</xref>
###xml 773 775 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b57">57</xref>
###xml 819 821 815 817 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b58">58</xref>
###xml 823 825 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b59">59</xref>
###xml 934 936 930 932 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b60">60</xref>
Gene expression levels from the asthma (n=26) and healthy subjects (n=11) were measured using Affymetrix GeneChip. From the 10 280 probe sets that met the inclusion criteria described in 'Methods', we identified 130 probe sets (representing 123 unique genes) that demonstrated a similar response to allergen in both the asthma and healthy groups. Similar response to allergen was defined as an average allergen-dependent fold change >/=1.5 in both groups, and no significant difference (FDR</=0.051) between the asthma and healthy groups with respect to allergen-dependent changes. The complete list of these 130 probe sets and their descriptions are included in supplementary Table S2. Genes on this list include IL-9 [46-49], IL-17 [50, 51], IL-22 [52-55] and IL-26 [56, 57] and genes such as CXCL1, CXCL2 and CXCL3 [58, 59], immune system genes that are involved in chemotaxis and activation of lymphoid cells, and MMP2 and MMP12 [60], implicated in degradation of the extra cellular matrix.
###end p 54
###begin title 55
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Peripheral blood mononuclear cell expression profile distinguishes asthma patients from healthy volunteers
###end title 55
###begin p 56
###xml 480 488 480 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD3">Table S3</xref>
###xml 658 664 658 664 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
###xml 948 955 948 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1125 1132 1125 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="tbl3">Table 3</xref>
###xml 1437 1439 1437 1439 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b61">61</xref>
###xml 1475 1477 1475 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 1479 1481 1479 1481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">63</xref>
###xml 1532 1534 1532 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">64</xref>
###xml 1535 1537 1535 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">68</xref>
###xml 1661 1663 1661 1663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b69">69</xref>
###xml 1709 1711 1709 1711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b70">70</xref>
Comparison of the expression levels of the 10 280 probe sets in the asthma and healthy subjects identified 167 probe sets (representing 153 unique genes) whose allergen-dependent changes differed significantly (FDR<0.051) between asthma and healthy subjects. These genes also showed an allergen-dependent fold change >1.5 in at least one group. The complete list of the 167 probe sets and, for each, the significance of the difference between the groups is shown in supplementary Table S3. A visualization of the differences between asthma and healthy subjects with respect to allergen-dependent changes in expression level of all 167 probe sets is shown in Fig. 1. The visualization was generated using an algorithm that groups subjects based on the similarities with respect to allergen-dependent gene expression changes. With one exception, all the healthy subjects were grouped together, and 22 of the 26 asthma subjects were grouped together. Table 3 shows 50 genes - a subset of genes that showed a significant difference between asthma and healthy subjects with respect to the response to allergen. The genes shown in Table 3 were associated with an allergen response of 1.5-fold or more increase or decrease in the asthma group, while having a <1.1-fold response to allergen in the healthy volunteer population. In this list are genes previously associated with the asthma phenotype including the Zap70 and LCK tyrosine kinases [61], the toll-like receptor 4 (TLR4) [62, 63], and complement component 3a receptor 1 (C3AR1) [64-68]. Allergen responsive genes not previously shown to be involved in the asthma phenotype included sialoadhesin (SN1-CD163) [69], and a disintegrin/metalloprotease, ADAM19 [70].
###end p 56
###begin p 57
Gene expression differences between asthma and healthy subjects in response to allergen
###end p 57
###begin p 58
Probes (genes) that changed 1.5-fold or greater in the asthma subjects (AOS) but changed less than 1.1-fold in the healthy volunteers (WHV), an FDR cut-off of </=0.051. (A) Genes up-regulated in asthma subjects 1.5-fold or higher compared with healthy volunteers. (B) Genes down-regulated by 1.5-fold or more in asthma subjects compared with healthy volunteers.FDR, false discovery rate.
###end p 58
###begin p 59
Visualization of the allergen-dependent expression pattern of 167 probe sets that differ significantly between asthma and healthy subjects: subjects are shown in columns, and genes in rows. Red indicates an allergen-dependent change higher than the mean. Green indicates an allergen-dependent change lower than the mean. Unsupervised clustering algorithm, which determines similarities between subjects independent of group membership, was used to generate this visualization. Subjects are grouped according to the degree of similarity in expression pattern. Note that, with one exception, the 11 healthy volunteers are grouped together, and that, with four exceptions, the 26 asthma subjects group together. H, healthy volunteer; A, asthmatic. The numbers following the letters A or H correspond to the individual donor (ID).
###end p 59
###begin p 60
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 274 282 274 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD1">Table S1</xref>
###xml 557 558 549 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 558 559 550 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
###xml 600 606 592 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig02">Fig. 2</xref>
###xml 865 866 857 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Confirmation of the Affymetrix results was carried out utilizing the custom TLDA described above using the sub-set samples used in the Affymetrix-based experiment that had sufficient RNA remaining (n=19 for the healthy group and n=9 for the asthma group. (See supplementary Table S1 for genes assayed by TLDA). Twenty-five genes were assayed both by GeneChip and by TLDA. The concordance between platforms was assessed by comparing the average allergen dependent log-2 fold change metric as measured by GeneChip and the average allergen-dependent DeltaDeltaCT metric as measured by TLDA. As shown in Fig. 2, excellent correlation was observed (Pearson's correlation=0.910) indicating a tight concordance in the results obtained from the two platforms. While the power of the GeneChip and TLDA were not comparable due to the differences in sample size and therefore P-values cannot be directly compared, the trend of the change was consistent for all genes. (The benefit of the increased sensitivity of the TLDA can be seen in the results for IL-18, where the difference detected by GeneChip did not pass the significance filters but a significant difference was observed by TLDA.)
###end p 60
###begin p 61
###xml 504 505 500 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</italic>
###xml 505 506 501 502 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">T</sub>
The correlation of the average log fold of allergen/no allergen gene expression between the Affymetrix GeneChip data and the low-density array data for all subjects. The black diagonal line represents the line of equality, and the lighter line represents the best-fit orthogonal regression line. The overall Pearson's correlation coefficient for the two measures of expression differences is 0.910. Affymetrix data is presented as frequency and the Taqman low density array data is presented as the DeltaCT value.
###end p 61
###begin p 62
Because atopic subjects constituted the majority (77%) of the asthma group and none of those in the healthy group were atopic, we examined whether the differences observed between asthma and healthy groups could be attributable to atopy status rather than asthma. Comparisons between the healthy group and the asthma group exclusive of the non-atopic group reduced the significance of association with the asthma in all cases, indicating that the observed differences were not attributable to atopy status (data not shown). Moreover, comparison of the atopic and non-atopic profiles did not reveal genes expressed at significantly different levels between the groups.
###end p 62
###begin title 63
###xml 16 17 16 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
A selective cPLA2alpha inhibitor alters the expression profile of allergen-responsive genes in asthma and healthy subjects
###end title 63
###begin p 64
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 523 524 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 569 577 561 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD4">Table S4</xref>
###xml 1251 1252 1243 1244 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Treatment of allergen-stimulated samples with the 5-lipoxgenase inhibitor, zileuton, did not cause changes that passed the filters set for significant effect. In contrast, the asthma-specific gene expression of a majority of the 167 probe sets associated with the asthma response to allergen was altered significantly in the presence of the WAY-196025 cPLA2alpha inhibitor when compared with allergen treatment alone. Results, including fold change and significance metrics in the comparison of groups with and without cPLA2alpha inhibition, are shown in supplementary Table S4. The probe sets fall into three distinct categories. In the first category, probes that correspond to genes that were up-regulated in asthma samples in response to allergen, such as ZAP70, LCK and mini-chromosome maintenance protein (MCM2), are reduced to the levels seen in the allergen-treated healthy controls. In the second category, genes that were initially down-regulated in the asthma samples in the presence of allergen, such as sialoadhesin (SN), pleckstrin (PLEK) and PLAU are up-regulated in the presence of inhibition. Lastly, there is a group of genes that were down-regulated in the presence of allergen in the asthmatic samples that are not affected by cPLA2alpha inhibition, these genes include CD84 and tissue inhibitor of metalloproteinase 3 (TIMP3).
###end p 64
###begin p 65
###xml 95 96 95 96 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 155 161 151 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig03">Fig. 3</xref>
###xml 625 631 621 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig01">Fig. 1</xref>
A hierarchical cluster analysis was performed to visualize the differences associated with cPLA2alpha inhibition for the 167 asthma-associated probe sets (Fig. 3). This visualization separated the asthma samples into the following three groups based on similarities in gene expression pattern: (1) asthma samples treated with allergen, (2) asthma samples treated with allergen and WAY-196025 and (3) a small population consisting of a mix of samples treated with allergen or allergen+WAY-196025. Interestingly, group 3 contains the same subjects who originally clustered with the healthy samples in response to allergen (see Fig. 1).
###end p 65
###begin p 66
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 633 636 629 632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+/&#8722;</sup>
###xml 652 653 648 649 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 744 745 736 737 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
Gene expression profiling demonstrates differential modulation of 167 probes in the asthma subjects in response to allergen in the presence of cPLA2alpha inhibitor. An unsupervised clustering algorithm, which determines similarities between subjects independent of group membership, was used to generate this visualization. Subjects are shown in columns, and genes in rows. Red indicates an allergen-dependent change higher than the mean. Green indicates an allergen-dependent change lower than the mean. Subjects are grouped according to the degree of similarity in expression pattern: A, asthmatic allergen-dependent fold change. A+/-, effect of cPLA2alpha inhibitor on allergen-dependent fold change. The numbers following the letters A or A+ correspond to the individual donor ID.
###end p 66
###begin title 67
Functional annotation of gene expression
###end title 67
###begin p 68
###xml 788 795 788 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4a</xref>
###xml 960 962 960 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b71">71</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b73">73</xref>
###xml 1468 1475 1468 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4b</xref>
To explore the functional relatedness of the allergen-responsive genes and identify associated pathways, the asthma-associated allergen-responsive gene list (167 probe set) was functionally annotated using IPA. Of the 167 probes initially entered into the analysis, 127 met the criteria for inclusion in pathway analysis. The criteria are based on the ingenuity knowledge base and on our statistical filters as described above. Seven well-populated functional networks were generated based on this information. The top functions for the networks created using IPA include immune and lymphatic system development and function, immune response, DNA replication, recombination and repair. The top-scoring network (Network 1) consisted of 35 genes involved in immune response and cell cycle (Fig. 4a). Genes in this network that were up-regulated in the asthma compared with the healthy subjects included the T cell receptor signalling genes CD3D, CD28 and ZAP70 [71-73]. As expected, based on the selection criteria, the expression levels (depicted by the gene colour intensities) in Network 1 for the healthy volunteer population looked very different from the asthma subjects. However, in the healthy subjects, a few of the genes were down-regulated in response to allergen similarly to the asthma subjects, but to a significantly lesser extent. This set of genes includes cathepsin B (CTSB), TIMP3 and CD36 antigen (collagen type I receptor, thrombospondin receptor) (Fig. 4b).
###end p 68
###begin p 69
###xml 92 93 92 93 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 454 455 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 627 627 619 619 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu5.jpg" mimetype="image"/>
###xml 654 654 646 646 <inline-graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="cea0038-1590-mu6.jpg" mimetype="image"/>
Allergen-responsive genes specific to the asthma group are modulated in response to the cPLA2alpha inhibitor. Network profile generated by Ingenuity Pathways Analysis (Ingenuity Systems). Genes are colour-coded according to whether they were up-regulated (red) or down-regulated (green) in the asthmatic samples compared with the healthy volunteer samples. (a) Asthma-specific allergen response, (b) healthy volunteer specific allergen response, (c) cPLA2alpha inhibitor affect on the asthma-specific allergen response. The symbols represent the type of protein that is coded for by the above genes. Included are: Transporter, ; transcription regulator, ; phosphatase, triangle up; enzyme/peptidase, open diamond; other, o.
###end p 69
###begin p 70
###xml 27 28 27 28 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 427 434 423 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4c</xref>
The striking effect of cPLA2alpha inhibition on allergen-induced asthma-associated gene expression changes can be illustrated by utilizing IPA. In this analysis, the expression values obtained in the presence of the inhibitor were overlaid into the gene set created based on asthma-specific allergen gene changes. Every gene in Network 1 in the asthma group has an altered level of expression in the presence of the inhibitor (Fig. 4c). In the healthy population, the few genes that were down-regulated in response to allergen in Network 1 are brought back to the non-allergen-stimulated background levels in the presence of the inhibitor (data not shown).
###end p 70
###begin title 71
Discussion
###end title 71
###begin p 72
###xml 72 80 72 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 566 568 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b74">74</xref>
###xml 569 571 565 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b76">76</xref>
###xml 730 738 726 734 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1267 1268 1263 1264 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The study reported here was conducted to investigate (a) how effects of in vitro exposure to allergen differ between asthma and healthy subjects, and (b) the involvement of the cPLA2alpha pathway in the processes identified as different between the two groups. We approached these important objectives by seeking to identify differences between the healthy and asthmatic phenotypes at the molecular level. Transcriptional profiling methods have been employed in numerous previous studies as exploratory screening tools independent of pre-existing disease paradigms [74-76]. This gene expression profiling study was conducted to compare, at the gene expression level, the response of asthmatic and healthy subjects PBMC samples to in vitro stimulation with a cocktail of common allergens. Subject samples in both groups responded to allergen as assessed by allergen-dependent cytokine stimulation both by ELISA, and, at the RNA level, by TLDA. In addition, using both Affymetrix GeneChip and TLDA platforms, we have identified many significant allergen-dependent gene expression differences between the asthma and healthy groups, and those differences are the focus of this study. We have extended this analysis further to include the effects of inhibition of the cPLA2alpha pathway on gene expression patterns significantly associated with the asthma group.
###end p 72
###begin p 73
###xml 118 126 118 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 720 722 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b77">77</xref>
###xml 724 726 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b78">78</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b49">49</xref>
###xml 742 744 742 744 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b79">79</xref>
###xml 991 993 991 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b80">80</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b81">81</xref>
###xml 1354 1356 1354 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b82">82</xref>
###xml 1358 1360 1358 1360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b83">83</xref>
###xml 1429 1431 1429 1431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b84">84</xref>
###xml 1433 1435 1433 1435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b85">85</xref>
###xml 1632 1640 1632 1640 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1730 1738 1730 1738 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1963 1971 1963 1971 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
The specific allergens used in this study are common environmental antigens and we report on many similarities in the in vitro responses to allergen among asthma and healthy subjects. Given the robust allergen responses that did not differ significantly between asthma and healthy subjects, our data indicate that the standard of care treatment that the asthma subjects were receiving did not prevent robust responses in this 6 day culture experimental system. Among genes that did not differ significantly between groups in the response to allergen are some chemokines and ILs. Some of these genes have previously been associated with the asthma phenotype including those involved in the T cell response such as IL-17 [77, 78] and IL-9 [49, 79] but in general, genes that have previously shown to be involved in the asthma subject response were modulated by allergen stimulation to a greater extent in the asthma group than in the healthy group. For example, the chemokine ligand 1 (CCL1) [80] and CCL18 [81] have recently been shown to be involved in the asthma phenotype and are up-regulated to a greater extent in the asthma group. Also contained within this gene set were genes not classically associated with the immune response, including those involved in protective stress responses such as the methallothionein (MT) gene family, MT2A and MT1X [82, 83] as well as those involved in glucose transport, GLUT-3 and GLUT-5 [84, 85]. Some of the genes with similarly increased expression in the presence of allergen in both the asthma and healthy volunteer groups included red blood cell specific genes, reflecting better 6 day in vitro survival of the small percentage of contaminating red blood cells under conditions of an in vitro immune response. This finding indicates that at least some of the allergen-dependent differential expression commonly observed in the two groups was due to differences in culture conditions in the presence and absence of an in vitro immune response to allergen. Such differences were, however, very similar in the two groups, supporting the conclusion that response to allergen occurred in both groups and that cell survival was similar in both groups.
###end p 73
###begin p 74
###xml 614 622 614 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="SD3">Table S3</xref>
###xml 729 730 729 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">N</italic>
###xml 751 752 751 752 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
Although the asthma group contained a majority of atopic subjects and the healthy group contained no atopic subjects, our findings tend to support a conclusion that the observed differences are attributable to asthma and not to atopy status. If the findings were attributable to atopy status, the significance of the association for any given gene with the group containing the aptopic samples would be predicted to increase when the non-atopic samples were excluded from analysis. The opposite was the case - the significance of association with the asthma group decreased for all genes reported in supplementary Table S3 when non-atopic asthmatics were removed from the analysis. Moreover, a head-to-head comparison of atopic (N=20) and non-atopic (n=6) subjects within the asthma group failed to reveal any significant differences. While failure to detect such differences could be due to the reduced power in this comparison, the results indicate that the differences observed in the asthma vs. healthy comparison are not attributable to atopy.
###end p 74
###begin p 75
###xml 277 285 275 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 569 577 563 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 965 967 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">64</xref>
###xml 968 970 962 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b68">68</xref>
###xml 986 988 980 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 990 992 984 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b63">63</xref>
###xml 1002 1004 996 998 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b86">86</xref>
###xml 1006 1008 1000 1002 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b87">87</xref>
###xml 1053 1055 1047 1049 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">64</xref>
###xml 1199 1201 1193 1195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b64">64</xref>
###xml 1329 1331 1323 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b88">88</xref>
###xml 1333 1335 1327 1329 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b89">89</xref>
###xml 1370 1372 1364 1366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b90">90</xref>
###xml 1374 1376 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b91">91</xref>
###xml 1418 1426 1412 1420 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1652 1654 1646 1648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b62">62</xref>
###xml 1656 1658 1650 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b92">92</xref>
###xml 1739 1741 1733 1735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b93">93</xref>
###xml 1825 1833 1819 1827 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1072 1076 <span type="species:ncbi:10090">mice</span>
###xml 1193 1197 <span type="species:ncbi:10090">mice</span>
Comparison of the expression levels of the 10 280 probe sets in the asthma and healthy subjects identified 167 probe sets (representing 153 unique genes) whose allergen-dependent changes differed significantly (FDR</=0.051) between asthma and healthy subjects following 6 days in vitro stimulation. In addition, TLDA analysis also identified IL-15, IL-18 and IL-13Ralpha1 as significantly associated with the response to allergen in the asthma group. The identification of a relatively large subset of genes that distinguish between asthma and healthy subjects in this in vitro study with relatively few subjects underscores the power of the global profiling approach in elucidating differences between groups that had not been observed previously. In fact, despite the standard of care therapy that the asthma subjects were receiving, several genes were identified that were previously shown to be involved in the asthma phenotype. These include complement C3AR1 [64-68] and the TLR4 [62, 63]. C3AR1 [86, 87] is involved in Th2 inflammatory responses [64]. C3AR knockout mice challenged with allergens have a decrease in AHR, airway eosinophils and IL-4 producing cells relative to wild-type mice [64]. The TLRs are a family of proteins that enhance certain cytokine gene transcription levels in response to pathogenic ligands [88, 89], and TLR4 responds to endotoxin [90, 91]. Our data demonstrate that, under these in vitro conditions (6 days in culture), the TLR4 was differentially modulated in asthma subjects in the presence of allergen. Recent evidence suggests that TLR4 is important in the asthma phenotype, although the data is conflicting [62, 92], but discrepancies may be attributable to differences in experimental systems [93]. The results reported here implicate TLR4 as associated with the asthma subjects' in vitro response to allergen. In a study comparing TLR4 expression levels in PBMC of asthma and healthy subjects before culture, and TLR4 expression levels show a highly significant association with asthma (manuscript in preparation). Also included in this list is the LCK tyrosine kinase. Two LCK GeneChip probe sets give discordant results. Such discordant results have been occasionally observed in other studies also, and Taqman analysis has indicated that discordance can be due to differences in expression of splice variants (data not shown), although in the case of LCK, the explanation of the discrepancy is unknown. TLDA analysis of LCK in the study reported here indicates down-regulated in asthma group.
###end p 75
###begin p 76
###xml 443 451 443 451 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b94">94</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b95">95</xref>
###xml 649 651 649 651 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b96">96</xref>
###xml 762 764 762 764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b97">97</xref>
###xml 801 803 801 803 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b98">98</xref>
###xml 1072 1074 1072 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b99">99</xref>
###xml 1121 1124 1121 1124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b100">100</xref>
###xml 1278 1279 1278 1279 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1321 1324 1321 1324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b101">101</xref>
###xml 354 358 <span type="species:ncbi:10090">mice</span>
The majority (approximately 80%) of the 167 differentially regulated probes have not been previously shown to be involved in the asthma phenotype. Among these are ATPase transporters, ATP6V0D1, ATP6V1A and ATP6AP1 and the CD antigens, CD163, CD169, CD84 and CD59, and PRNP, which is expressed on a variety of immune cell types. Macrophages obtained from mice that do not express PRNP have higher rates of phagocytosis than the wild-type cells in vitro [94]. Available data on the importance of macrophages in the asthmatic phenotype does not inform on the significance of macrophage PRNP in the asthma phenotype [95]. However, alveolar macrophages [96] play a role in innate immune responses and these responses have been shown to affect the severity of asthma [97] and bronchoconstriction in asthma [98]. Genes modulated in the allergen-treated PBMC of asthma subjects that have not previously been associated with asthma also include the following MCMs: MCM2, MCM5 and MCM7 along with polycomb group ring finger 4 protein, BMI1. BMI1 is involved in lymphoproliferation [99] and is implicated in T cell differentiation [100]. Therefore, the lymphoproliferative effect of BMI1 could be important in the asthmatic phenotype, perhaps playing a role in increasing the amount of CD4+ T cells in the lungs of asthma subjects [101].
###end p 76
###begin p 77
###xml 701 704 701 704 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b102">102</xref>
###xml 854 855 854 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 862 863 862 863 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 1044 1047 1044 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b103">103</xref>
###xml 1108 1111 1108 1111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b104">104</xref>
Global profiling also revealed allergen-dependent, asthma-associated differential expression of several genes involved in regulating the oxidative state that had previously not been associated with the asthma phenotype. Reactive oxygen species are beneficial in host defence mechanisms. However, the production of these species can be pro-inflammatory in diseases such as asthma. Included among these are a glutathione peroxidase, glutathione peroxidase 7 (GPX7), the nonselenoperoxidase, peroxiredoxin 2 (PRDX2) and the microsomal glutathione S-transferase 3 (MGST3) gene. GPX proteins, such as GPX-1 have previously shown to be responsible for suppression of 5-LO activity in a monocytic cell line [102], but this is the first evidence that GPX7 may also be a factor in the asthmatic response to allergen. MGST3 is responsible for the conversion of LTA4 to LTC4, and both are important mediators of the arachidonic acid pathway. Lastly, the peroxiredoxin family of proteins are responsible for the reduction of a broad spectrum of peroxides [103] and have been shown to be up-regulated in lung carcinomas [104], but have not previously been associated with asthma.
###end p 77
###begin p 78
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 117 119 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b24">24</xref>
###xml 121 123 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b25">25</xref>
###xml 225 228 221 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b105">105</xref>
###xml 370 373 366 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b106">106</xref>
###xml 391 392 387 388 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 518 521 514 517 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b107">107</xref>
###xml 528 529 524 525 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 590 593 582 585 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b105">105</xref>
###xml 641 643 633 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 659 660 651 652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 725 728 713 716 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b108">108</xref>
###xml 735 743 723 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 840 841 828 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 890 891 874 875 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1025 1026 1005 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1307 1314 1281 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4c</xref>
###xml 1371 1378 1345 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig04">Fig. 4a</xref>
###xml 1461 1462 1435 1436 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1520 1521 1490 1491 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1604 1607 1574 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b109">109</xref>
###xml 1669 1670 1639 1640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1990 1993 1956 1959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b110">110</xref>
###xml 545 549 <span type="species:ncbi:10090">mice</span>
###xml 567 572 <span type="species:ncbi:10090">mouse</span>
cPLA2alpha catalyses the first step in the biosynthesis of arachidonic acid-derived leukotrienes and prostaglandins [24, 25] and is theoretically an attractive target for inhibition in the treatment of inflammatory diseases [105]. Anti-leukotriene therapy acting either at the level of 5-lipoxygenase or CysLT1 receptor has proven beneficial in the treatment of asthma [106]. Prostaglandin D2 and other prostaglandins may also mediate the hallmarks of asthma including airway inflammation AHR and bronchoconstriction [107]. cPLA2alpha knock-out mice are resistant in mouse model of asthma [105], and inhibitor WAY-196025 used in this study [27] and other cPLA2alpha inhibitors have shown efficacy in animal models of asthma [108]. The in vitro allergen challenge model system was used in this study to evaluate the molecular effects of cPLA2alpha inhibition in PBMCs. The inhibition of cPLA2alpha had striking effects on the allergen-related, asthma-associated profile. The hierarchical clustering analysis revealed that cPLA2alpha inhibition affected a shift in the asthma-associated allergen-dependent profile to a profile closely resembling the profile of healthy volunteers with approximately 80% of the probes changing significantly (FDR</=0.051) with treatment. As discussed in 'Results' and shown in Fig. 4c, all T cell responsive genes in the pathway depicted in Fig. 4a were significantly changed towards the levels in the healthy subject group by cPLA2alpha inhibition. This result is noteworthy given that CD4+ T cells are believed critical for the development and maintenance of the disease [109]. Other immune-related genes were also down-regulated by cPLA2alpha inhibition including, CD28 and CD3D, IL-21R and the transcription factor, high-mobility group box 1 protein (HMGB1). The HMGB1 result is of particular interest as this protein has been shown to be a distal mediator of acute inflammation of the lung linked to an increased production of pro-inflammatory cytokines [110].
###end p 78
###begin p 79
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 159 160 155 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 403 405 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b27">27</xref>
###xml 407 409 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="b30">30</xref>
The effect of cPLA2alpha inhibition on gene expression is more noteworthy in that it was not replicated by zileuton - suggesting that the effect seen with cPLA2alpha inhibition is not strictly mediated by leukotrienes, but is at least partially due to the inhibition of a greater range of lipid mediators including the prostaglandins, platelet-activating factor and products of 12 and 15-lipoxygenases [27, 30]. As mentioned above, the effects of zileuton on gene expression did not pass the filters set for significance in the GeneChip portion of the study and are much more subtle. However, protein analysis revealed a significant effect of zileuton on IL-13 production at the 6 day time-point assayed, indicating that gene expression changes may have been detectable at earlier untested time-points.
###end p 79
###begin p 80
###xml 129 137 129 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 171 179 171 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 361 362 361 362 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 547 555 543 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Peripheral blood is easily accessible, and the transcriptome of PBMCs can be studied both directly upon collection and following in vitro stimulation. We have employed an in vitro model system to identify disease-related transcriptional profiles and to model the response of PBMCs in the clinical setting to drug exposure using an experimental inhibitor of cPLA2alpha. The results of this global profiling study have yielded broad ranging findings on the significant differences and similarities between asthma and healthy subjects as revealed by in vitro allergen responsiveness. The scope and size of the study have allowed us to confirm some previously reported asthma associations, and to discover novel association that were not predictable based on the pre-existing information. These results clearly demonstrate that global transcriptional profiling has utility as a sensitive exploratory tool to study molecular mechanisms of disease and pathways affected by candidate therapeutics.
###end p 80
###begin p 81
###xml 30 38 <span type="species:ncbi:9606">patients</span>
We gratefully acknowledge the patients who donated samples, and the study teams at the two clinical sites and at Wyeth; we especially thank Ian Wyglendowski for all his work as lead clinical scientist for this study and Marina Shen for performing the zileuton and WAY-196025 activity assays. We also thank Debra Ellis for help with assay preparation and logistics. We thank Tom Goralski and the entire team at Expression Analysis for running GeneChip microarrays.
###end p 81
###begin title 82
References
###end title 82
###begin article-title 83
Asthma: mechanisms of disease persistence and progression
###end article-title 83
###begin article-title 84
The health economics of asthma and rhinitis. I. Assessing the economic impact
###end article-title 84
###begin article-title 85
The pathophysiology of asthma
###end article-title 85
###begin article-title 86
Requirement for IL-13 independently of IL-4 in experimental asthma
###end article-title 86
###begin article-title 87
Interleukin-13 in asthma pathogenesis
###end article-title 87
###begin article-title 88
###xml 13 19 <span type="species:ncbi:10090">murine</span>
Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins
###end article-title 88
###begin article-title 89
Functional diversity of helper T lymphocytes
###end article-title 89
###begin article-title 90
Asthma
###end article-title 90
###begin article-title 91
New drugs for asthma
###end article-title 91
###begin article-title 92
Bronchial hyperreactivity to sulfur dioxide: physiologic and political implications
###end article-title 92
###begin article-title 93
Airway inflammation is present during clinical remission of atopic asthma
###end article-title 93
###begin article-title 94
Significant variability in response to inhaled corticosteroids for persistent asthma
###end article-title 94
###begin article-title 95
Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma clinical research network
###end article-title 95
###begin article-title 96
Genetics and the variability of treatment response in asthma
###end article-title 96
###begin article-title 97
Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis
###end article-title 97
###begin article-title 98
Long-acting beta2-agonists in asthma: safety concerns
###end article-title 98
###begin article-title 99
Adverse skin reactions to inhaled corticosteroids
###end article-title 99
###begin article-title 100
###xml 78 83 <span type="species:ncbi:9606">human</span>
Allergen-induced interleukin-9 production in vitro: correlation with atopy in human adults and comparison with interleukin-5 and interleukin-13
###end article-title 100
###begin article-title 101
Allergen-specific increase in interleukin (IL)-4 and IL-5 secretion from peripheral blood mononuclear cells during birch-pollen immunotherapy
###end article-title 101
###begin article-title 102
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Effects of IL-4 and IL-13 on total and allergen specific IgE production by cultured PBMC from allergic patients determined with recombinant pollen allergens
###end article-title 102
###begin article-title 103
###xml 135 143 <span type="species:ncbi:9606">patients</span>
Study of the Th1/Th2 balance, including IL-10 production, in cultures of peripheral blood mononuclear cells from birch-pollen-allergic patients
###end article-title 103
###begin article-title 104
Cytokine production in PBMC from allergics and non-allergics following in vitro allergen stimulation
###end article-title 104
###begin article-title 105
###xml 71 79 <span type="species:ncbi:9606">children</span>
Allergen-induced cytokine secretion in atopic and non-atopic asthmatic children
###end article-title 105
###begin article-title 106
Properties and regulation of cytosolic phospholipase A2
###end article-title 106
###begin article-title 107
Cystosolic phospholipase A2
###end article-title 107
###begin article-title 108
Blockade of eosinophil migration and airway hyperresponsiveness by cPLA2-inhibition
###end article-title 108
###begin article-title 109
###xml 11 12 11 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Indole cPLA2alpha inhibitors: Discovery and In vitro and In vivo characterization of 4-{3-[5-Chloro-2(2-{[(3,4-dichlorobenzyl)sulfonyl]amino}ethyl)-1-(diphenylmethyl)-1H-indol-3-yl]propyl}benzoic Acid, Efipladib
###end article-title 109
###begin article-title 110
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis
###end article-title 110
###begin article-title 111
Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment
###end article-title 111
###begin article-title 112
TNF-alpha induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation
###end article-title 112
###begin article-title 113
Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues
###end article-title 113
###begin article-title 114
The molecular biology of leukocyte chemoattractant receptors
###end article-title 114
###begin article-title 115
Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4
###end article-title 115
###begin article-title 116
###xml 79 87 79 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 49 55 <span type="species:ncbi:9796">equine</span>
Endotoxin-induced production of interleukin 6 by equine peritoneal macrophages in vitro
###end article-title 116
###begin article-title 117
Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third national health and nutrition examination survey
###end article-title 117
###begin article-title 118
Discovery of Ecopladib, an indole inhibitor of cytosolic phospholipase A2alpha
###end article-title 118
###begin article-title 119
###xml 55 61 <span type="species:ncbi:10090">murine</span>
Identification of novel cytosolic phospholipase A(2)s, murine cPLA(2){delta}, {epsilon}, and {zeta}, which form a gene cluster with cPLA(2){beta}
###end article-title 119
###begin article-title 120
###xml 82 87 <span type="species:ncbi:10090">mouse</span>
Function, activity, and membrane targeting of cytosolic phospholipase A(2)zeta in mouse lung fibroblasts
###end article-title 120
###begin article-title 121
Molecular characterization of cytosolic phospholipase A2-beta
###end article-title 121
###begin article-title 122
Expression monitoring by hybridization to high-density oligonucleotide arrays
###end article-title 122
###begin article-title 123
Evaluation of normalization procedures for oligonucleotide array data based on spiked cRNA controls
###end article-title 123
###begin article-title 124
Controlling the false discovery rate: a practical and powerful approach to multiple testing
###end article-title 124
###begin article-title 125
###xml 98 106 <span type="species:ncbi:9606">patients</span>
In vitro allergen-induced mRNA expression of signaling lymphocytic activation molecule by PBMC of patients with allergic rhinitis is increased during specific pollen immunotherapy
###end article-title 125
###begin article-title 126
Interleukin-16 inhibits interleukin-13 production by allergen-stimulated blood mononuclear cells
###end article-title 126
###begin article-title 127
Interleukin 9 promotes influx and local maturation of eosinophils
###end article-title 127
###begin article-title 128
###xml 146 161 <span type="species:ncbi:10090">transgenic mice</span>
Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice
###end article-title 128
###begin article-title 129
Interleukin 9-induced in vivo expansion of the B-1 lymphocyte population
###end article-title 129
###begin article-title 130
###xml 44 59 <span type="species:ncbi:10090">transgenic mice</span>
Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness
###end article-title 130
###begin article-title 131
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human IL-17: a novel cytokine derived from T cells
###end article-title 131
###begin article-title 132
Interleukin-17
###end article-title 132
###begin article-title 133
###xml 29 34 <span type="species:ncbi:9606">human</span>
Interleukin (IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R
###end article-title 133
###begin article-title 134
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor
###end article-title 134
###begin article-title 135
Cloning and characterization of IL-10-related T cell-derived inducible factor (IL-TIF), a novel cytokine structurally related to IL-10 and inducible by IL-9
###end article-title 135
###begin article-title 136
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides
###end article-title 136
###begin article-title 137
IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha
###end article-title 137
###begin article-title 138
IL-10 subfamily members: IL-19, IL-20, IL-22, IL-24 and IL-26
###end article-title 138
###begin article-title 139
###xml 92 97 <span type="species:ncbi:9606">human</span>
The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes
###end article-title 139
###begin article-title 140
###xml 52 57 <span type="species:ncbi:9606">human</span>
Expression and regulation of chemokine receptors in human natural killer cells
###end article-title 140
###begin article-title 141
How matrix metalloproteinases regulate cell behavior
###end article-title 141
###begin article-title 142
Inhibitors of the tyrosine kinase signaling cascade for asthma
###end article-title 142
###begin article-title 143
Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity
###end article-title 143
###begin article-title 144
###xml 67 71 <span type="species:ncbi:10090">mice</span>
The role of Toll-like receptor 4 in environmental airway injury in mice
###end article-title 144
###begin article-title 145
###xml 92 98 <span type="species:ncbi:10090">murine</span>
Absence of the complement anaphylatoxin C3a receptor suppresses Th2 effector functions in a murine model of pulmonary allergy
###end article-title 145
###begin article-title 146
A role for the C3a anaphylatoxin receptor in the effector phase of asthma
###end article-title 146
###begin article-title 147
Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis
###end article-title 147
###begin article-title 148
###xml 14 25 <span type="species:ncbi:10141">guinea pigs</span>
Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in allergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma
###end article-title 148
###begin article-title 149
Variations in the C3, C3a receptor, and C5 genes affect susceptibility to bronchial asthma
###end article-title 149
###begin article-title 150
The macrophage scavenger receptor CD163
###end article-title 150
###begin article-title 151
###xml 44 49 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of a human metalloprotease disintegrin - a novel marker for dendritic cell differentiation
###end article-title 151
###begin article-title 152
The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation
###end article-title 152
###begin article-title 153
Deconstructing the form and function of the TCR/CD3 complex
###end article-title 153
###begin article-title 154
The B7 family of immune-regulatory ligands
###end article-title 154
###begin article-title 155
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood
###end article-title 155
###begin article-title 156
Blood cell gene expression profiling in rheumatoid arthritis. Discriminative genes and effect of rheumatoid factor
###end article-title 156
###begin article-title 157
###xml 67 75 <span type="species:ncbi:9606">patients</span>
Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells
###end article-title 157
###begin article-title 158
###xml 52 57 <span type="species:ncbi:9606">human</span>
IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines
###end article-title 158
###begin article-title 159
Interleukin-17 as a recruitment and survival factor for airway macrophages in allergic airway inflammation
###end article-title 159
###begin article-title 160
###xml 32 40 <span type="species:ncbi:9606">patients</span>
Segmental allergen challenge in patients with atopic asthma leads to increased IL-9 expression in bronchoalveolar lavage fluid lymphocytes
###end article-title 160
###begin article-title 161
The CC chemokine Ligand (CCL)-1 is released into the airways of atopic asthmatics
###end article-title 161
###begin article-title 162
Involvement of CCL18 in allergic asthma
###end article-title 162
###begin article-title 163
Possible role for metallothionein in protection against radiation-induced oxidative stress. Kinetics and mechanism of its reaction with superoxide and hydroxyl radicals
###end article-title 163
###begin article-title 164
Regulation of metallothionein gene expression by oxidative stress and metal ions
###end article-title 164
###begin article-title 165
Structure, function, and regulation of the mammalian facilitative glucose transporter gene family
###end article-title 165
###begin article-title 166
The mammalian facilitative glucose transporter (GLUT) family
###end article-title 166
###begin article-title 167
###xml 46 51 <span type="species:ncbi:9606">human</span>
Molecular cloning and characterization of the human anaphylatoxin C3a receptor
###end article-title 167
###begin article-title 168
###xml 26 31 <span type="species:ncbi:9606">human</span>
Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells
###end article-title 168
###begin article-title 169
Toll-like receptors and innate immunity
###end article-title 169
###begin article-title 170
Toll-like receptors: critical proteins linking innate and acquired immunity
###end article-title 170
###begin article-title 171
CD11b/CD18 acts in concert with CD14 and Toll-like receptor (TLR) 4 to elicit full lipopolysaccharide and taxol-inducible gene expression
###end article-title 171
###begin article-title 172
Toll-like receptors
###end article-title 172
###begin article-title 173
Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide
###end article-title 173
###begin article-title 174
Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen
###end article-title 174
###begin article-title 175
The cellular prion protein modulates phagocytosis and inflammatory response
###end article-title 175
###begin article-title 176
The alveolar macrophage: the forgotten cell in asthma
###end article-title 176
###begin article-title 177
###xml 78 98 78 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Klebsiella pneumonia</italic>
###xml 71 77 <span type="species:ncbi:10090">murine</span>
Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival
###end article-title 177
###begin article-title 178
Severity of asthma is related to endotoxin in house dust
###end article-title 178
###begin article-title 179
Effect of inhaled endotoxin on bronchial reactivity in asthmatic and normal subjects
###end article-title 179
###begin article-title 180
###xml 81 84 <span type="species:ncbi:8790">Emu</span>
###xml 90 105 <span type="species:ncbi:10090">transgenic mice</span>
Pertubation of B and T cell development and predisposition to lymphomagenesis in Emu Bmi1 transgenic mice require the Bmi1 RING finger
###end article-title 180
###begin article-title 181
###xml 114 119 <span type="species:ncbi:9606">human</span>
Distinct BMI-1 and EZH2 expression patterns in thymocytes and mature T cells suggest a role for Polycomb genes in human T cell differentiation
###end article-title 181
###begin article-title 182
Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma
###end article-title 182
###begin article-title 183
Glutathione peroxidase-1 but not -4 is involved in the regulation of cellular 5-lipoxygenase activity in monocytic cells
###end article-title 183
###begin article-title 184
A family of novel peroxidases, peroxiredoxins
###end article-title 184
###begin article-title 185
###xml 44 49 <span type="species:ncbi:9606">human</span>
Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress
###end article-title 185
###begin article-title 186
Role of cytosolic phospholipase A2 in allergic response and parturition
###end article-title 186
###begin article-title 187
Treatment of asthma with antileukotrienes: first line or last resort therapy?
###end article-title 187
###begin article-title 188
Emerging roles of DP and CRTH2 in allergic inflammation
###end article-title 188
###begin article-title 189
###xml 111 114 <span type="species:ncbi:10116">rat</span>
Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2 alpha: optimization of in vitro potency and rat pharmacokinetics for oral efficacy
###end article-title 189
###begin article-title 190
###xml 13 19 <span type="species:ncbi:10090">murine</span>
Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia
###end article-title 190
###begin article-title 191
HMG-1 as a mediator of acute lung inflammation
###end article-title 191
###begin title 192
Supporting Information
###end title 192
###begin p 193
Additional Supporting Information may be found in the online version of this article.
###end p 193
###begin p 194
Genes assayed on TLDA.
###end p 194
###begin p 195
Allergen-responsive genes in healthy and asthmatic subjects.
###end p 195
###begin p 196
One hundred and fifty-three genes differentially regulated in asthmatics in response to allergen.
###end p 196
###begin p 197
WAY196025 - cPLA2 inhibitor.
###end p 197
###begin p 198
Please note: Blackwell Publishing is not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.
###end p 198

